| Year |
Citation |
Score |
| 2016 |
Hassing HA, Fares S, Larsen O, Pad H, Hauge M, Jones RM, Schwartz TW, Hansen HS, Rosenkilde MM. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochemical Pharmacology. PMID 27569424 DOI: 10.1016/J.Bcp.2016.08.018 |
0.304 |
|
| 2013 |
Han S, Thatte J, Buzard DJ, Jones RM. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. Journal of Medicinal Chemistry. 56: 8224-56. PMID 23865723 DOI: 10.1021/Jm4005626 |
0.422 |
|
| 2012 |
Buzard DJ, Lehmann J, Han S, Jones RM. GPR119 agonists 2009-2011. Pharmaceutical Patent Analyst. 1: 285-99. PMID 24236842 DOI: 10.4155/Ppa.12.33 |
0.3 |
|
| 2011 |
Buzard D, Han S, Thoresen L, Moody J, Lopez L, Kawasaki A, Schrader T, Sage C, Gao Y, Edwards J, Barden J, Thatte J, Fu L, Solomon M, Liu L, ... ... Jones RM, et al. Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1Pâ‚ agonists. Bioorganic & Medicinal Chemistry Letters. 21: 6013-8. PMID 21852130 DOI: 10.1016/J.Bmcl.2011.05.110 |
0.314 |
|
| 2008 |
Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, ... ... Jones RM, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. Journal of Medicinal Chemistry. 51: 5172-5. PMID 18698756 DOI: 10.1021/Jm8006867 |
0.365 |
|
| 2005 |
Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proceedings of the National Academy of Sciences of the United States of America. 102: 9050-5. PMID 15932946 DOI: 10.1073/Pnas.0501112102 |
0.555 |
|
| 2003 |
Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC, Jones RM, Portoghese PS, Carlezon WA. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. The Journal of Pharmacology and Experimental Therapeutics. 305: 323-30. PMID 12649385 DOI: 10.1124/Jpet.102.046433 |
0.572 |
|
| 2002 |
Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology. 163: 412-9. PMID 12373442 DOI: 10.1007/S00213-002-1038-X |
0.596 |
|
| 2001 |
Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS, Levine AS. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Research. 909: 75-80. PMID 11478923 DOI: 10.1016/S0006-8993(01)02624-5 |
0.596 |
|
| 2001 |
Sharma SK, Jones RM, Metzger TG, Ferguson DM, Portoghese PS. Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. Journal of Medicinal Chemistry. 44: 2073-9. PMID 11405645 DOI: 10.1021/Jm010095V |
0.612 |
|
| 2000 |
Stevens WC, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. Journal of Medicinal Chemistry. 43: 2759-69. PMID 10893314 DOI: 10.1021/Jm0000665 |
0.625 |
|
| 2000 |
Jones RM, Portoghese PS. 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. European Journal of Pharmacology. 396: 49-52. PMID 10822054 DOI: 10.1016/S0014-2999(00)00208-9 |
0.601 |
|
| 2000 |
Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. Journal of Medicinal Chemistry. 43: 1573-6. PMID 10780914 DOI: 10.1021/Jm000059G |
0.614 |
|
| 2000 |
McCurdy CR, Jones RM, Portoghese PS. Investigation of phenolic bioisosterism in opiates: 3-sulfonamido analogues of naltrexone and oxymorphone. Organic Letters. 2: 819-21. PMID 10754685 DOI: 10.1021/Ol005561+ |
0.526 |
|
| 1998 |
Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. Journal of Medicinal Chemistry. 41: 4911-4. PMID 9836606 DOI: 10.1021/Jm9805182 |
0.577 |
|
| 1995 |
Garratt PJ, Jones R, Tocher DA, Sugden D. Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. Journal of Medicinal Chemistry. 38: 1132-9. PMID 7707316 DOI: 10.1021/Jm00007A010 |
0.576 |
|
| Show low-probability matches. |